Proliant Biologicals

Proliant Biologicals

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Proliant Health & Biologicals is a private, established manufacturer of biological proteins and ingredients, positioned as a B2B supplier to innovators in human and animal health. Its core competency lies in a proprietary, closed-loop manufacturing system that guarantees high purity and traceability for products like immunoglobulins (e.g., Immunolin) and colostrum. With over 20 years of experience, the company generates revenue through custom formulation, contract manufacturing, and direct supply, partnering with diagnostic, pharmaceutical, and nutraceutical companies to enhance their end products.

AntibodiesBiologics

Technology Platform

Proprietary closed-loop manufacturing system for the purification and fractionation of animal-derived proteins (e.g., immunoglobulins from bovine colostrum/plasma), ensuring high purity, traceability, and consistency for B2B partners.

Opportunities

The growing global markets for biologics manufacturing, diagnostic components, and scientifically-backed nutritional ingredients present significant expansion opportunities.
PHB's closed-loop, dual-source manufacturing model is a key differentiator for partners seeking supply chain resilience and high-purity raw materials.

Risk Factors

Key risks include dependence on agricultural supply chains for bovine materials, potential customer concentration, and exposure to regulatory scrutiny in the highly controlled diagnostics and pharma sectors.
Reputational risk related to quality control or animal-derived sourcing must be carefully managed.

Competitive Landscape

PHB competes with other specialty ingredient manufacturers and contract research organizations (CROs) in the life science tools sector. Its primary competitive advantages are its integrated closed-loop manufacturing, which ensures purity and traceability, and its deep expertise in animal-derived protein fractionation, serving a niche that synthetic recombinant producers may not address.